Evid Based Nurs doi:10.1136/eb-2012-100958
  • Primary healthcare
  • Systematic review with meta-analysis

Orlistat reduces weight but its cost–effectiveness remains unclear

  1. Lennert Veerman
  1. School of Population Health, University of Queensland, Brisbane, Queensland, Australia
  1. Correspondence to: Dr Lennert Veerman
    The University of Queensland, School of Population Health, Herston Road, Herston, Queensland 4006, Australia; l.veerman{at}

Commentary on: Ara R, Blake L, Gray L, et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technol Assess 2012;16:1–195.

Implications for practise and research

  • Ara and colleagues studied the effectiveness and cost effectiveness of weight-reducing drugs and found that they provide statistically significant weight loss and are worth the investment.

  • The analysis contains several unwarranted assumptions, notably around the amount of weight lost, subsequent weight regained and the permanency of weight loss. Definitive conclusions cannot be drawn from this study.


Obesity is a large and growing health problem. For patients unable to achieve sufficient weight loss by improving their lifestyle, weight-reducing drugs are a treatment option. This study aimed to evaluate the effectiveness and cost effectiveness of three pharmacological interventions (orlistat, sibutramine and …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article